GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oyster Point Pharma Inc (NAS:OYST) » Definitions » 1-Year ROIIC %

Oyster Point Pharma (Oyster Point Pharma) 1-Year ROIIC % : -765.21% (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Oyster Point Pharma 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Oyster Point Pharma's 1-Year ROIIC % for the quarter that ended in Sep. 2022 was -765.21%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Oyster Point Pharma's 1-Year ROIIC % or its related term are showing as below:

OYST's 1-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -3.665 vs OYST: -765.21

Oyster Point Pharma 1-Year ROIIC % Historical Data

The historical data trend for Oyster Point Pharma's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oyster Point Pharma 1-Year ROIIC % Chart

Oyster Point Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
1-Year ROIIC %
- - - - -

Oyster Point Pharma Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oyster Point Pharma's 1-Year ROIIC %

For the Biotechnology subindustry, Oyster Point Pharma's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oyster Point Pharma's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oyster Point Pharma's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Oyster Point Pharma's 1-Year ROIIC % falls into.



Oyster Point Pharma 1-Year ROIIC % Calculation

Oyster Point Pharma's 1-Year ROIIC % for the quarter that ended in Sep. 2022 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -158.453 (Sep. 2022) - -79.958 (Sep. 2021) )/( 23.062 (Sep. 2022) - 12.804 (Sep. 2021) )
=-78.495/10.258
=-765.21%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Oyster Point Pharma  (NAS:OYST) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Oyster Point Pharma 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Oyster Point Pharma's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oyster Point Pharma (Oyster Point Pharma) Business Description

Traded in Other Exchanges
N/A
Address
202 Carnegie Center, Suite 109, Princeton, NJ, USA, 08540
Oyster Point Pharma Inc is a biopharmaceutical company focused on the development of pharmaceutical therapies to treat ocular surface diseases. Its product candidate OC-01 is a nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.
Executives
Ozawa Clare director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Donald J Santel director 4362 24TH STREET, SAN FRANCISCO CA 94114
George Christopher Eliades director C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
John Snisarenko officer: Chief Commercial Officer C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Invopps Gp Iv, L.l.c. director, 10 percent owner 126 EAST 56TH STREET, 20THFLOOR, NEW YORK NY 10022
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Jeffrey Nau director, officer: President and CEO 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
Daniel Lochner officer: Chief Financial Officer 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Kkr Group Partnership L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001
Invopps Iv Us, L.p. director, 10 percent owner 126 EAST 56TH STREET, 20TH FLOOR, NEW YORK NY 10022

Oyster Point Pharma (Oyster Point Pharma) Headlines

From GuruFocus